Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Like normal cells, cancer cells require amino acids for growth, maintenance, and cell signaling, and L-type amino acid transporters (LATs) are the delivery vehicles that supply them. Metastatic, castration-resistant prostate cancer (CRPC) cells are highly dependent on LATs to deliver the amino acid leucine that the cells need for growth and proliferation, according to a study published in the Journal of the National Cancer Institute.
To investigate the function of LATs in prostate cancer, Qian Wang, Ph.D., of the Origins of Cancer Laboratory, Centenary Institute, Sydney, Australia, and colleagues studied LAT3 expression in tissue samples from prostate cancer patients, analyzed the function of LATs in cancer cells in vitro, used microarray data to determine which genes and pathways are associated with LAT function, and assessed the role of LAT1 and LAT3 in tumor formation, growth, and metastasis in mice.
The researchers found that LAT3 was expressed at all stages of prostate cancer and that inhibition of LAT proteins inhibits nutrient signaling pathways and over 100 metastasis-related genes, including E2F transcription factors, resulting in cell cycle inhibition. In mice injected with prostate cancer cells, tumor formation, metastasis, and cell cycle progression were all inhibited when the LAT1 or LAT3 gene was knocked out.
The authors conclude that "Targeting LAT transporters, thereby inhibiting leucine uptake, may offer a new therapeutic opportunity for metastatic CRPC, affecting tumor growth and metastasis through inhibition of M-phase cell cycle and mTORC1 signaling pathways." Wang et al. note, however, that further investigation into the long-term effects of leucine deprivation is needed, as well as the effects on other cell types and resistance mechanisms.
In an accompanying editorial, Andrew R. Tee, Ph.D., of the Institute of Cancer and Genetics at Cardiff University, Wales, writes, "Such new evidence explains why malignant prostate cancer has an appetite for amino acids, where these amino acids are quickly utilized to drive their growth and proliferation." Tee adds that this discovery will have huge implications for both prostate cancer studies and therapies.
JNCI J Natl Cancer Inst (2013) doi: 10.1093/jnci/djt252 First published online: September 19, 2013
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Prostate / Prostate Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Journal of the National Cancer Institute. "Researchers reveal that proteins delivering leucine to prostate cancer cells may offer therapeutic targets." Medical News Today. MediLexicon, Intl., 22 Sep. 2013. Web.
7 Dec. 2013. <http://www.medicalnewstoday.com/releases/266376>
Journal of the National Cancer Institute. (2013, September 22). "Researchers reveal that proteins delivering leucine to prostate cancer cells may offer therapeutic targets." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266376.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.